Evidence map›Paper›PMID 41524385›Full record

SynthesisFuture oncology (London, England)2026

Matching-adjusted indirect treatment comparison of A+AVD vs PET-guided ABVD in newly diagnosed advanced Hodgkin lymphoma.

Fjoralba Kristo, Alexa Molinari, Zhiyi Lan, Victoria Paly, Ramsha Khan, Abbey Poirier, Hoora Moradian, Bipin N Savani, Athanasios Zomas, Ajibade Ashaye

Abstract readComparative StudySystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fjoralba KristoGlobal Evidence and Outcomes, Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Alexa MolinariHealth Economics, Takeda Pharmaceuticals America, Inc., Lexington, MA, USA.
Zhiyi LanEvidence, Value, and Access, Cytel Inc., Cambridge, MA, USA.
Victoria PalyTakeda Pharmaceuticals America, Inc., Lexington, MA, USA.
Ramsha KhanEvidence, Value, and Access, Cytel Inc., Cambridge, MA, USA.
Abbey PoirierEvidence, Value, and Access, Cytel Inc., Cambridge, MA, USA.
Hoora MoradianEvidence, Value, and Access, Cytel Inc., Cambridge, MA, USA.
Bipin N SavaniOncology Clinical Science, Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Athanasios ZomasGlobal Medical Affairs Oncology, Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Ajibade AshayeGlobal Evidence and Outcomes, Takeda Development Center Americas, Inc., Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe study team investigated the relative efficacy of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) versus positron emission tomography (PET)-guided doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) among previously untreated adults with advanced Hodgkin lymphoma via matching-adjusted indirect comparison (MAIC). MATERIALS &

methodsA systematic literature review identified ECHELON-1 (A+AVD), RATHL, and SWOG S0816 as feasible trials referencing a targeted comparator (PET-guided ABVD). Effect modifiers/prognostic variables were identified by clinical expert opinion and Cox regression using long-term ECHELON-1 individual patient-level data. Weighted Cox regressions generated hazard ratios (HR) and 95% confidence intervals (CI) representing A+AVD versus PET-guided ABVD relative treatment effect on overall survival (OS) and progression-free survival (PFS).

resultsOS improved significantly with A+AVD versus PET-guided ABVD (HR [95% CI] 0.48 [0.32, 0.73], p < 0.001 [RATHL]; 0.49 [0.26, 0.92], p = 0.043 [SWOG S0816]). PFS significantly favored A+AVD over PET-guided ABVD in both trial comparisons. While the proportional hazards assumption did not hold for these comparisons, 8-year restricted mean survival time and piecewise Cox regression results aligned with the main results.

conclusionMAIC results indicated durable A+AVD treatment benefits in adults with newly diagnosed advanced Hodgkin lymphoma versus PET-guided regimens evaluated in RATHL and SWOG S0816.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHodgkin DiseasePositron-Emission TomographyAdultBleomycinBrentuximab VedotinDacarbazineDoxorubicinFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisTreatment OutcomeVinblastineBleomycinBrentuximab VedotinDacarbazineDoxorubicinVinblastinebrentuximab vedotin, doxorubicin, vinblastine, and dacarbazinedoxorubicin, bleomycin, vinblastine, and dacarbazineHodgkin lymphomaMatching-adjusted indirect comparisonoverall survivalpositron emission tomography-guidedprogression-free survival

Identifiers

PMID41524385
PMCPMC12977273

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.